{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T03:52:47Z","timestamp":1789271567565,"version":"build-2803163510"},"reference-count":70,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,12,10]],"date-time":"2009-12-10T00:00:00Z","timestamp":1260403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Neurochemistry"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:sec><jats:label\/><jats:p><jats:italic>J. Neurochem.<\/jats:italic>(2010)<jats:bold>112<\/jats:bold>, 1131\u20131137.<\/jats:p><\/jats:sec><jats:sec><jats:title>Abstract<\/jats:title><jats:p>The anti\u2010parkinsonian drug, rasagiline [<jats:italic>N<\/jats:italic>\u2010propargyl\u20101\u2010(<jats:italic>R<\/jats:italic>)\u2010aminoindan; Azilect\u00ae], is a secondary cyclic benzylamine and indane derivative, which provides irreversible, potent monoamine oxidase\u2010B (MAO\u2010B) inhibition and possesses neuroprotective and neurorestorative activities. A prospective clinical trial has shown that rasagiline confers significant symptomatic improvement and demonstrated alterations in Parkinson\u2019s disease progression. Rasagiline is primarily metabolized by hepatic cytochrome P\u2010450 to form its major metabolite, 1\u2010(<jats:italic>R<\/jats:italic>)\u2010aminoindan, a non\u2010amphetamine, weak reversible MAO\u2010B inhibitor compound. Recent studies indicated the potential neuroprotective effect of 1\u2010(<jats:italic>R<\/jats:italic>)\u2010aminoindan, suggesting that it may contribute to the overall neuroprotective and antiapoptotic effects of its parent compound, rasagiline. This review article briefly highlights the molecular mechanisms underlying the neuroprotective properties of the active metabolite of rasagiline, 1\u2010(<jats:italic>R<\/jats:italic>)\u2010aminoindan, supporting the valuable potential of rasagiline for disease modification.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1471-4159.2009.06542.x","type":"journal-article","created":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T01:55:49Z","timestamp":1260496549000},"page":"1131-1137","source":"Crossref","is-referenced-by-count":61,"title":["The neuroprotective mechanism of 1\u2010(<i>R<\/i>)\u2010aminoindan, the major metabolite of the anti\u2010parkinsonian drug rasagiline"],"prefix":"10.1111","volume":"112","author":[{"given":"Orit","family":"Bar\u2010Am","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Amit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moussa B. H.","family":"Youdim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,2,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4547(19991101)58:3<456::AID-JNR12>3.0.CO;2-S"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01548-5"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.01047.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(02)00332-4"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2003.10.067"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2004.02425.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.05-3794fje"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2007.04777.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0506266"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0026-895X(24)26436-1","article-title":"Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde\u20103\u2010phosphate dehydrogenase to a dimer","volume":"57","author":"Carlile G. W.","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_8_12_1","first-page":"295","article-title":"Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism","volume":"23","author":"Carlsson A.","year":"1980","journal-title":"Adv. Biochem. Psychopharmacol."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(00)00643-3"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005277935"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1039\/B715270A"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1997.68041400.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01271228"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s007020170012"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-004-0254-4"},{"key":"e_1_2_8_20_1","first-page":"31","volume-title":"Monoamine Oxidase Inhibitors \u2013 The State of the Art","author":"Finberg J. P. M.","year":"1981"},{"key":"e_1_2_8_21_1","first-page":"95","article-title":"Pharmacology and neuroprotective properties of rasagiline","volume":"48","author":"Finberg J. P.","year":"1996","journal-title":"J. Neural Transm. Suppl."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199803090-00026"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.3.823"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00929-7"},{"key":"e_1_2_8_25_1","first-page":"223","article-title":"Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer\u2019s disease and Down syndrome","volume":"61","author":"Kim S. H.","year":"2001","journal-title":"J. Neural Transm. Suppl."},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200119030-00008"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21-09-02929.2001"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(98)00315-9"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresrev.2004.12.027"},{"key":"e_1_2_8_30_1","first-page":"171","article-title":"Neurotoxins induce apoptosis in dopamine neurons: protection by N\u2010propargylamine\u20101(R)\u2010 and (S)\u2010aminoindan, rasagiline and TV1022","volume":"60","author":"Maruyama W.","year":"2000","journal-title":"J. Neural Transm. Suppl."},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0047-6374(00)00144-5"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2001.tb03641.x"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2001.00448.x"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s007020200038"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(03)00211-8"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2003.08.005"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1586\/ern.09.68"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-211-33328-0_8"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22218"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809335"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12640-009-9064-7"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1978.tb00883.x"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.39.25436"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2006.07.020"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(97)00603-5"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-6499-0_29"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s007020050182"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-6499-0_30"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm020120c"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12640-009-9030-4"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(99)01761-5"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.04-1916fje"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-009-0225-x"},{"issue":"1","key":"e_1_2_8_54_1","first-page":"S124","article-title":"Neuroprotective and neuritogenic activities of novel multimodal iron chelating drugs in motor neuron\u2010like NSC\u201034 cells and transgenic mouse model of Amyotrophic Lateral Sclerosis","volume":"39","author":"Weinreb O.","year":"2009","journal-title":"J. Mol. Neurosci."},{"key":"e_1_2_8_55_1","first-page":"S157","article-title":"TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer\u2019s disease","volume":"60","author":"Weinstock M.","year":"2000","journal-title":"J. Neural Transm."},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/1098-2299(200007\/08)50:3\/4<216::AID-DDR4>3.0.CO;2-Z"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2001.tb03622.x"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-306-47593-1_33"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(03)00053-8"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-005-0299-z"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-005-0299-z"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.02-0198fje"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-0078fje"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.05-4910fje"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498258609043515"},{"key":"e_1_2_8_66_1","first-page":"737","article-title":"Rasagiline: an anti\u2010Parkinson drug with neuroprotective activity","volume":"3","author":"Youdim M. B. H.","year":"2003","journal-title":"Future Drugs"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015131516649"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703826"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2001.tb03656.x"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.20350"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2008.05330.x"}],"container-title":["Journal of Neurochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1471-4159.2009.06542.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1471-4159.2009.06542.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T19:30:24Z","timestamp":1739475024000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1471-4159.2009.06542.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,2]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1111\/j.1471-4159.2009.06542.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1471-4159.2009.06542.x","archive":["Portico"],"relation":{},"ISSN":["0022-3042","1471-4159"],"issn-type":[{"value":"0022-3042","type":"print"},{"value":"1471-4159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,2]]}}}